CN115135332A - 艰难梭菌增殖抑制剂 - Google Patents
艰难梭菌增殖抑制剂 Download PDFInfo
- Publication number
- CN115135332A CN115135332A CN202180015419.2A CN202180015419A CN115135332A CN 115135332 A CN115135332 A CN 115135332A CN 202180015419 A CN202180015419 A CN 202180015419A CN 115135332 A CN115135332 A CN 115135332A
- Authority
- CN
- China
- Prior art keywords
- clostridium difficile
- enterococcus faecalis
- bacteria
- dead
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract description 42
- 230000035755 proliferation Effects 0.000 title claims abstract description 17
- 239000003112 inhibitor Substances 0.000 title claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 59
- 241000194032 Enterococcus faecalis Species 0.000 claims abstract description 47
- 229940032049 enterococcus faecalis Drugs 0.000 claims abstract description 47
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 9
- 239000003899 bactericide agent Substances 0.000 claims abstract description 8
- 239000000645 desinfectant Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000012459 cleaning agent Substances 0.000 claims abstract description 5
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000003966 growth inhibitor Substances 0.000 abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 239000004310 lactic acid Substances 0.000 description 15
- 235000014655 lactic acid Nutrition 0.000 description 15
- -1 sorbitan fatty acid esters Chemical class 0.000 description 14
- 208000037384 Clostridium Infections Diseases 0.000 description 9
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 9
- 206010054236 Clostridium difficile infection Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000007921 spray Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 229940124350 antibacterial drug Drugs 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 229940035437 1,3-propanediol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108700029181 Bacteria lipase activator Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- BFPJYWDBBLZXOM-UHFFFAOYSA-L potassium tellurite Chemical compound [K+].[K+].[O-][Te]([O-])=O BFPJYWDBBLZXOM-UHFFFAOYSA-L 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Agronomy & Crop Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明提供艰难梭菌增殖抑制剂。艰难梭菌增殖抑制剂，其含有粪肠球菌的死菌。本发明也提供艰难梭菌增殖抑制用非口服药物制剂、杀菌剂、消毒剂、抗菌剂、除菌剂或清洗剂。
Description
技术领域
本发明涉及艰难梭菌增殖抑制剂。
背景技术
艰难梭菌感染(Clostridioides(Clostridium)difficile infection，CDI)大多由于由使用抗菌药等造成的消化道菌群的受损而发病。其大部分常使用抗菌药，并且年龄增长、有无基础疾病等为患病因素。
CDI大部分为胃肠道感染，症状多为腹泻、腹痛，有时也伴有发热、白细胞增多，如果发展为重症则有时也会因中毒性巨结肠、肠梗阻、消化道穿孔而致死。
已确认有在消化道带有艰难梭菌而不显现症状的“携带者”，在经常使用抗菌药的住院治疗患者中，这样的“携带者”较为多见。艰难梭菌与CDI患者及无症状携带者的粪便一起被***，并污染包括医疗工作者的手指在内的环境，从而作为医疗相关感染成为问题。因此，其为在需要进行如换尿布这样的***护理的老年人较多住院，且没有充分进行包括对抗菌药的合理使用的感染管理的医疗现场中常见的感染。但是，在滥用抗菌药、没有充分进行感染管理的医疗机构中，由于对CDI的关注及知识较低，因此没有适当诊断本疾病而表面上发生率较低的情况常被视为问题。
像这样，在医疗机构、老年人设施中，CDI处于容易慢性化的环境，且正在对采取感染预防对策的必要性进行讨论。
现有技术文献
非专利文献
非专利文献1
艰难梭菌感染的基础和临床，Modern media，56卷10号，2010
www.eiken.co.jp/modern_media/backnumber/pdf/MM1010_01.pdf
发明内容
发明要解决的问题
本发明的目的在于提供艰难梭菌增殖抑制剂。
用于解决问题的手段
本发明人等进行了深入研究，结果发现粪肠球菌(Enterococcus faecalis)的死菌能够抑制艰难梭菌的增殖，从而完成了本发明。
本发明的要点如下所述。
(1)艰难梭菌增殖抑制剂，其含有粪肠球菌的死菌。
(2)艰难梭菌增殖抑制用非口服药物制剂，其含有粪肠球菌的死菌。
(3)艰难梭菌增殖抑制用杀菌剂、消毒剂、抗菌剂、除菌剂或清洗剂，其含有粪肠球菌的死菌。
(4)外用药物，其含有粪肠球菌的死菌。
(5)卫生用品，其含有粪肠球菌的死菌。
发明效果
根据本发明，能够抑制艰难梭菌的增殖。
本说明书包含作为本申请的优先权的基础的日本专利申请特愿2020-43740的说明书和/或附图中记载的内容。
附图说明
[图1]示出实施例1的试验结果(活菌数(×103CFU/mL))。○：对照组，□：低浓度组(被测物质浓度：0.64mg/mL)，△：高浓度组(被测物质浓度：64mg/mL)。和对照组比较时的显著差异(**：p＜0.01)。
具体实施方式
以下，更详细地对本发明的实施方式进行说明。
本发明提供艰难梭菌增殖抑制剂，其含有粪肠球菌的死菌。本发明也提供使用粪肠球菌的死菌来抑制艰难梭菌的增殖的方法。另外，本发明提供抑制艰难梭菌的增殖的方法中所使用的药剂，其含有粪肠球菌的死菌。
粪肠球菌(Enterococcus faecalis)作为具有生物应答调节物质(BiologicalResponse Modifier，BRM)活性(药学志112：919-925 1992；药学志113：396-399 1992；动物临床医学3：11-20 1994)的乳球菌而为人所知。粪肠球菌EF-2001株可从日本Berumu株式会社(东京都千代田区永田町2-14-3)获得。
粪肠球菌-2001株可取自正常人的粪便，且具有下述性质。
为革兰氏阳性球菌。菌落外形(Trypto-Soya琼脂培养基，培养24小时)：直径1.0mm，光滑，正圆形，白色菌落形态：球形至卵圆形(1.0×1.5μm)，在液体培养基中常形成链。不形成芽胞。兼性厌氧。使葡萄糖发酵而产生乳酸(最终pH4.3)。不产气。过氧化氢酶阴性。在10～45℃增殖(最适为37℃)。在pH9.6、6.5％NaCl、40％胆汁中增殖。0.04％亚碲酸钾阳性。0.01％四唑鎓阳性。0.1％亚甲基蓝乳阳性。使精氨酸水解。使苦杏仁苷、纤维二糖、果糖、半乳糖、葡萄糖、甘油、乳糖、麦芽糖、甘露糖、甘露醇、核糖、水杨苷、蔗糖、松三糖、山梨糖醇发酵而产生酸。60℃、30分钟耐性。使酪蛋白、明胶消化。将酪氨酸脱羧成为酪胺。兰斯菲尔德(Lancefield)抗原分组D。GC％35.0±1.0％
粪肠球菌可以是死菌，也可以对菌体实施破坏处理(均质处理、酶处理、超声波处理等)、加热、干燥(冷冻干燥、喷雾干燥等)等处理。活菌可通过加热处理而成为死菌。可对粪肠球菌的死菌期待肠道免疫活化作用。菌体粒径可为0.05μm～50μm，优选为0.08～20μm，更优选为0.1～10μm。菌体可在和稀释剂混合后，添加糊料而制成颗粒状。稀释剂或糊料可从作为添加到食品或药物中的物质而被许可的材料中选择。
粪肠球菌的死菌对艰难梭菌的增殖抑制性地起作用。通过抑制艰难梭菌的增殖，可预防和/或治疗艰难梭菌感染。可将粪肠球菌的死菌作为非口服制剂的有效成分而用于药物。另外，可将粪肠球菌的死菌作为杀菌剂的有效成分而用于药物、准药品。可将粪肠球菌的死菌作为消毒剂的有效成分而用于医疗器械的杀菌、外用(人、动物的皮肤)。可将粪肠球菌的死菌作为抗菌剂或除菌剂的有效成分而用于卫生用品。此外，通过将粪肠球菌的死菌用于身体、器具、设备、设施等的清洗，可抑制艰难梭菌的增殖。因此，本发明提供艰难梭菌增殖抑制用杀菌剂、消毒剂、抗菌剂、除菌剂或清洗剂，其含有粪肠球菌的死菌。另外，本发明也提供外用药物，其含有粪肠球菌的死菌。并且，本发明也提供卫生用品，其含有粪肠球菌的死菌。
在本发明中，在使用粪肠球菌的死菌进行杀菌、消毒、除菌或清洗时，可将粪肠球菌的死菌应用于人、非人动物的身体表面(皮肤、粘膜等)。或者，可将粪肠球菌的死菌应用于人、非人动物的身体可能接触的器具、设备、设施等的表面，也可喷雾或散布到人、非人动物呼吸的空间。
可将含有粪肠球菌的死菌的杀菌剂、消毒剂、抗菌剂、除菌剂或清洗剂制剂化为喷雾剂(气雾剂、泵压喷雾剂)、贴剂(水性型糊剂、油性型膏剂等)、软膏剂、霜剂、凝胶剂、外用固体剂、外用液剂(搽剂、乳液剂等)等剂型，而用作外用药物(外用药物组合物)、准药品或卫生用品。
作为制剂的基剂，可以使用烃类(凡士林、液态石蜡等)、高级脂肪酸及其酯类(己二酸、肉豆蔻酸、棕榈酸、硬脂酸、它们的酯等)、蜡类(蜂蜡、羊毛脂等)、高级醇(鲸蜡醇、硬脂醇等)等油性成分、水、多元醇(甘油、1，3-丙二醇、1，2-丙二醇等)、低级醇(乙醇、异丙醇等)等水性成分、表面活性剂(硬脂酸甘油酯、山梨醇酐脂肪酸酯、聚氧乙烯醇醚、羧酸盐、硫酸酯盐等)、保存剂(对羟基苯甲酸酯类等)、抗氧化剂(亚硫酸氢钠、抗坏血酸等)、pH调节剂(柠檬酸水合物、乳酸、乙酸等)等。
粪肠球菌的死菌在制剂中的含量根据制剂的种类而有所不同，通常为0.001～100质量％，优选为0.01～100质量％。
粪肠球菌的死菌的使用量只要为能够确认到艰难梭菌的增殖抑制效果的量即可，根据剂型、应用部位、患者的年龄、体重、基础疾病的有无、种类等而有所不同，例如，在成人的情况下，每次的使用量可换算为粪肠球菌的死菌的量，对皮肤或鼻腔、口腔内粘膜以0.01～500mg/mL左右、优选为0.05～300mg/mL左右、更优选为0.1～100mg/mL左右的浓度，1天使用1次至多次(例如2次、3次、4次、5次左右)。在将粪肠球菌的死菌应用于人、非人动物以外(应用于例如器具、设备、设施等的表面、空间)时，也能够以和上述相同的使用量使用。
粪肠球菌的死菌也可添加到纱布、脱脂棉、酒精棉、棉棒、绷带、口罩、手套、创可贴、外科胶带、擦拭用品(毛巾、片材等)、湿巾布、湿毛巾、肥皂、***用凝固剂等中。
含有粪肠球菌的死菌的非口服药物制剂可以制剂化为外用剂[喷雾剂(气雾剂、泵压喷雾剂)、贴剂(水性型糊剂、油性型膏剂等)、软膏剂、霜剂、凝胶剂、外用固体剂、外用液剂(搽剂、乳液剂等)]、注射剂、输液、眼科用剂(滴眼剂、洗眼剂、眼软膏剂等)、栓剂等剂型，而用作药物。
作为外用剂(喷雾剂等)的基剂，可以使用烃类(凡士林、液态石蜡等)、高级脂肪酸及其酯类(己二酸、肉豆蔻酸、棕榈酸、硬脂酸、它们的酯等)、蜡类(蜂蜡、羊毛脂等)、高级醇(鲸蜡醇、硬脂醇等)等油性成分、水、多元醇(甘油、1，3-丙二醇、1，2-丙二醇等)、低级醇(乙醇、异丙醇等)等水性成分、表面活性剂(硬脂酸甘油酯、山梨醇酐脂肪酸酯、聚氧乙烯醇醚、羧酸盐、硫酸酯盐等)、保存剂(对羟基苯甲酸酯类等)、抗氧化剂(亚硫酸氢钠、抗坏血酸等)、pH调节剂(柠檬酸水合物、乳酸、乙酸等)等。外用剂可应用于皮肤、鼻腔或口腔粘膜。
注射剂及输液可以使用溶剂[水性溶剂(蒸馏水、生理盐水、林格氏溶液等)、非水性溶剂(乙醇、1，2-丙二醇、植物油等)]、增溶剂(谷氨酸、天冬氨酸、聚山梨糖醇酯80等)、保存剂(苯扎氯铵、苄索氯铵等)、稳定剂(亚硫酸盐、焦亚硫酸钠等)、乳化剂、悬浮剂(卵磷脂、单硬脂酸铝等)、缓冲剂(酸、碱、柠檬酸盐等)、着色剂等而进行制剂化。制剂可在制造的最终工序中杀菌，或者利用无菌操作法制造。另外，也可制造无菌的冷冻干燥品，并在其使用前溶解于无菌注射用蒸馏水或其他溶剂中而使用。注射剂及输液可应用到皮肤内或通过皮肤或粘膜而应用到体内。也可通过鼻腔而应用。作为施用法，可列举：皮内施用、皮下施用、肌内施用、静脉内施用、鼻腔内施用。
滴眼剂可以使用溶剂[水性溶剂(灭菌纯化水、生理盐水等)、非水性溶剂(乙醇、1，2-丙二醇、植物油等)]、缓冲液、等渗剂、保存剂(对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、苯扎氯铵、苄索氯铵等)、增稠剂(甲基纤维素、硫酸软骨素等)、悬浮剂(非离子性表面活性剂等)、着色剂等而进行制剂化。
洗眼剂可以使用生理盐水、硼酸溶液、苄索氯铵、缓冲液等制备。
眼软膏剂可以使用烷烃、液态石蜡等作为基剂，并根据需要添加保存剂、稳定剂等而进行制剂化。
栓剂可以使用基剂[油脂性基剂(可可脂、椰子油、棕榈仁油等)、水溶性基剂(甘油明胶、聚乙二醇等)]、表面活性剂(卵磷脂、胆固醇等)等而进行制剂化。
粪肠球菌的死菌在药物制剂中的含量根据制剂的种类而有所不同，通常为0.001～100质量％，优选为0.01～100质量％。
粪肠球菌的死菌的施用量只要为能够确认到艰难梭菌的增殖抑制效果的量即可，根据剂型、应用部位、患者的年龄、体重、基础疾病的有无、种类等而有所不同，例如，在成人的情况下，每次的施用量可换算为粪肠球菌的死菌的量，以0.01～500mg/mL左右、优选为0.05～300mg/mL左右、更优选为0.1～100mg/mL左右的浓度，1天施用1次至多次(例如2次、3次、4次、5次左右)。
另外，也可以通过将本发明的抗菌剂涂布于产品上或捏合到产品中，制造抗菌毛巾、抗菌塑料餐具产品、抗菌玩具类、抗菌PC相关产品、抗菌文具等。
实施例
以下结合实施例详细地对本发明进行说明，但本发明并不限定于这些实施例。
[实施例1]乳酸菌EF-2001株对于艰难梭菌的作用确认试验
概要
对乳酸菌对于艰难梭菌的作用进行研究。
相对于接种菌液1mL，以0.65mL的比例添加乳酸菌的低浓度液(1.63mg/mL)或高浓度液(163mg/mL)，在乳酸菌的浓度为0.64mg/mL或64mg/mL的条件下对艰难梭菌进行厌氧培养。测定培养开始时、培养后12小时、24小时及48小时的活菌数。
在乳酸菌的低浓度(0.64mg/mL)及高浓度(64mg/mL)条件下，均在培养后12小时、24小时及48小时和对照组相比，确认到艰难梭菌的活菌数显著减少。由此推测乳酸菌对艰难梭菌的增殖抑制性地起作用。
材料及方法
1.被测物质
1.1.被测物质
名称：乳酸菌粉末EF-2001(日本Berumu株式会社)(经加热杀菌的粪肠球菌，直径为500nm＝0.5μm)
性状：黄褐色粉末
保管条件：室温(18.0～28.0℃)，遮光，防湿
保管场所：试验设施的被测物质保管室的保管库
2.施用样本
2.1.被测物质的制备方法
称量(电子天平：XP205DR，Mettler Toledo株式会社)必要量的乳酸菌粉末EF-2001，利用GAM肉汤(参照15.3.4.)以成为500mg/mL的方式制备。使用该500mg/mL溶液，利用GAM肉汤以成为163mg/mL及1.63mg/mL的方式稀释。由于乳酸菌粉末会沉淀，因此充分搅拌并悬浮。临用时制备。
3.病原微生物
3.1.使用菌株
艰难梭菌(Clostridioides(Clostridium)difficile)(ATCC43255，下文称为艰难梭菌(C.difficile))
3.2.保存条件
在超低温冰箱(设定温度：-80℃，MDF-394AT，三洋电机株式会社)中冻存至使用时。
3.3.试剂
(1)GAM琼脂培养基(日水制药株式会社)
(2)GAM肉汤培养基(日水制药株式会社)
(3)生理盐水(大塚制药工厂株式会社)
3.4.GAM肉汤的制备
称量GAM肉汤粉末29.5g，悬浮于注射用水(大塚制药工厂株式会社)500mL中，然后进行高压灭菌器(LSX-500，Tomy Seiko株式会社)处理(115℃，15分钟)。制备后在冷藏条件下保存。
3.5.前培养
将艰难梭菌(C.difficile)的保存菌株解冻，接种至GAM琼脂培养基中，放入填充有脱氧剂的厌氧袋中，在设定37℃的恒温器(ILE800，Yamato科学株式会社)中培养5天。培养后，将菌落挑起，加入GAM肉汤培养基中，放入填充有脱氧剂的厌氧袋中，在设定37℃的恒温器中培养2天。将培养后的培养液作为接种菌原液。
3.6.接种菌液的制备及活菌数测定
将利用GAM肉汤培养基将接种菌原液稀释10倍而成的溶液作为接种菌液。
关于活菌数确认，取接种菌液的一部分，用生理盐水适当稀释，涂抹到GAM琼脂培养基后，放入填充有脱氧剂的厌氧袋中，在设定37℃的恒温器中培养5天。利用手动菌落计数器(CC-1，Azwan株式会社)测量培养后的菌落数，并算出接种菌液1mL中所含的活菌数。其结果，接种菌液浓度为2.8×105CFU/mL。
使用后的剩余接种菌液在进行高压灭菌器(LSX-500，Tomy Seiko株式会社)处理(121℃，15分钟)后废弃。
4.试验方法
4.1.增殖抑制试验
4.1.1.试验组构成
显示浓度为混合后的最终浓度。
*：添加有GAM肉汤。
4.1.2.试验方法
相对于接种菌液1mL，分别以0.65mL的比例向试管中添加所制备的被检溶液(1.63mg/mL液及163mg/mL液)，放入填充有脱氧剂的厌氧袋中，在设定37℃的恒温器中培养。在培养开始时、培养12、24及48小时后分别取出试管，取培养液的一部分，并适当稀释，将培养液原液、稀释液涂抹到CCFA培养基(日本Becton Dickinson株式会社)，然后在设定37℃的恒温器中厌氧培养5天。利用手动菌落计数器测量培养后的菌落数，并算出活菌数。作为对照，添加GAM肉汤代替被检溶液。样本数设为5。
5.结果汇总
关于活菌数，算出平均值及标准误差。
对活菌数，以对照组相对于样本组，使用威尔科克森秩和检验(Wilcoxon ranksum test)进行显著差异检验。
显著性水平是将5％设为显著，并分别分成低于5％及低于1％进行表示。
需要说明的是，统计分析使用市售的统计程序(SAS***：SAS Institute Japan)。
试验成果
将试验结果示于表1、附录1-1～1-3及图1。
对照组的艰难梭菌的活菌数在培养开始时为360.0±75.9(×103CFU/mL)，培养12小时后为3680.0±239.6(×103CFU/mL)，培养24小时后为3880.0±475.8(×103CFU/mL)，培养48小时后为33020.0±2267.5(×103CFU/mL)。
低浓度组的艰难梭菌的活菌数在培养开始时为306.0±22.7(×103CFU/mL)，培养12小时后为33.2±4.9(×103CFU/mL)，培养24小时后为27.1±6.7(×103CFU/mL)，培养48小时后为15.7±4.9(×103CFU/mL)。和对照组相比，在培养后12小时、24小时及48小时确认到活菌数显著减少。
高浓度组的艰难梭菌的活菌数在培养开始时为300.0±22.1(×103CFU/mL)，培养12小时后为12.0±1.1(×103CFU/mL)，培养24小时后为8.4±3.4(×103CFU/mL)，培养48小时后为5.7±3.2(×103CFU/mL)。和对照组相比，在培养后12小时、24小时及48小时确认到活菌数显著减少。
考察
通过经时性地测定活菌数来研究乳酸菌对于艰难梭菌的作用。
在乳酸菌的低浓度(0.64mg/mL)及高浓度(64mg/mL)条件下，均在培养后12小时、24小时及48小时和对照组相比，确认到艰难梭菌的活菌数显著减少。由此推测乳酸菌对艰难梭菌的增殖抑制性地起作用。
(表1)
表1.活菌数
各值表示平均值(×103CFU/mL)±S.E.
和对照组有显著差异(**：p＜0.01)
(附录1-1～1-3)
附录1-1各组活菌数
对照组
单位：×103CFU/mL
附录1-2各组活菌数
低浓度组
单位：×103CFU/mL
和对照组有显著差异(**：p＜0.01)
NS：和对照组没有显著差异
WL：利用威尔科克森检验进行分析
附录1-3各组活菌数
高浓度组
单位：×103CFU/mL
和对照组有显著差异(**：p＜0.01)
NS：和对照组没有显著差异
WL：利用威尔科克森检验进行分析
[产品例1]除菌液、抗菌喷雾剂、除菌片
以下述配方制备除菌液。
(配方)
乳酸菌粉末EF-2001(日本Berumu株式会社)(经加热杀菌的粪肠球菌，直径为500nm＝0.5μm)0.6质量％
甘油0.05质量％
癸酸单甘油酯0.50质量％
乙醇50质量％
纯化水余量
总量100质量％
将上述溶液填充到市售的泵压式喷雾容器中，制造抗菌喷雾剂。另外，将上述溶液浸泡到纱布或纸巾上而制造除菌片。
将本说明书所引用的所有刊物、专利及专利申请直接作为参考而并入本说明书中。
工业实用性
本发明可用于艰难梭菌感染的预防和/或治疗、杀菌、消毒、除菌、清洗等。
Claims (5)
1.艰难梭菌增殖抑制剂，其含有粪肠球菌的死菌。
2.艰难梭菌增殖抑制用非口服药物制剂，其含有粪肠球菌的死菌。
3.艰难梭菌增殖抑制用杀菌剂、消毒剂、抗菌剂、除菌剂或清洗剂，其含有粪肠球菌的死菌。
4.外用药物，其含有粪肠球菌的死菌。
5.卫生用品，其含有粪肠球菌的死菌。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-043740 | 2020-03-13 | ||
| JP2020043740 | 2020-03-13 | ||
| PCT/JP2021/008920 WO2021182377A1 (ja) | 2020-03-13 | 2021-03-08 | クロストリディオイデス ディフィシル菌増殖抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115135332A true CN115135332A (zh) | 2022-09-30 |
Family
ID=77671738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180015419.2A Pending CN115135332A (zh) | 2020-03-13 | 2021-03-08 | 艰难梭菌增殖抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230144328A1 (zh) |
| EP (1) | EP4119150A1 (zh) |
| JP (1) | JPWO2021182377A1 (zh) |
| KR (1) | KR20220154089A (zh) |
| CN (1) | CN115135332A (zh) |
| AU (1) | AU2021235383A1 (zh) |
| CA (1) | CA3171324A1 (zh) |
| WO (1) | WO2021182377A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823014A (zh) * | 2018-10-10 | 2021-05-18 | 营养株式会社 | 艰难梭菌感染的预防和/或治疗剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002540900A (ja) * | 1999-04-14 | 2002-12-03 | ガネデン バイオテック， インコーポレイテッド | 衛生製品に関連する微生物感染の阻害方法 |
| JP4903559B2 (ja) * | 2004-03-16 | 2012-03-28 | コンビ株式会社 | 家畜・家禽類又は魚介類の感染防除剤 |
| JP5308619B2 (ja) * | 2006-06-05 | 2013-10-09 | 株式会社アドバンス | 健康食品 |
| GB2460468A (en) * | 2008-05-30 | 2009-12-02 | Univ Northampton | Vapour of a citrus essential oil blend and its antimicrobial properties |
| ES2895851T3 (es) * | 2016-04-01 | 2022-02-22 | Trioptotec Gmbh | Dispersión de fotosensibilizador y uso de la misma |
| JP7206721B2 (ja) | 2018-09-13 | 2023-01-18 | マツダ株式会社 | 電動発電機の制御装置 |
-
2021
- 2021-03-08 CN CN202180015419.2A patent/CN115135332A/zh active Pending
- 2021-03-08 EP EP21768495.0A patent/EP4119150A1/en not_active Withdrawn
- 2021-03-08 JP JP2022507167A patent/JPWO2021182377A1/ja active Pending
- 2021-03-08 CA CA3171324A patent/CA3171324A1/en active Pending
- 2021-03-08 KR KR1020227027329A patent/KR20220154089A/ko unknown
- 2021-03-08 WO PCT/JP2021/008920 patent/WO2021182377A1/ja active Application Filing
- 2021-03-08 US US17/802,611 patent/US20230144328A1/en active Pending
- 2021-03-08 AU AU2021235383A patent/AU2021235383A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823014A (zh) * | 2018-10-10 | 2021-05-18 | 营养株式会社 | 艰难梭菌感染的预防和/或治疗剂 |
Non-Patent Citations (4)
| Title |
|---|
| CHOI ET AL.: "Heat-Killed Enterococcus faecalis EF-2001 Ameliorates Atopic Dermatitis in a Murine Model", NUTRIENTS, vol. 8, 5 March 2016 (2016-03-05), pages 1 - 11 * |
| GU ET AL.: "Protective Effects of Enterococcus Faecalis 2001 (EF 2001) against Radiation-induced Leukocytes Damage in Mice", JOURNAL OF JUNSHIN GAKUEN UNIVERSITY，FACULTY OF HEALTH SCIENCES, vol. 2, 31 March 2013 (2013-03-31), pages 55 * |
| MALAMOU ET AL.: "Inhibition of Clostridium difficile by faecal streptococci", J MED MICROBIOL, vol. 15, no. 4, 30 November 1982 (1982-11-30), pages 569 - 574 * |
| MANSOUR ET AL.: "Inhibition of Clostridium difficile in Mice Using a Mixture of Potential Probiotic Strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: Novel Candidates to Control C. difficile Infection (CDI)", PROBIOTICS ANTIMICROB PROTEINS, vol. 10, no. 3, 11 May 2017 (2017-05-11), pages 1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021182377A1 (ja) | 2021-09-16 |
| US20230144328A1 (en) | 2023-05-11 |
| CA3171324A1 (en) | 2021-09-16 |
| AU2021235383A1 (en) | 2022-11-10 |
| KR20220154089A (ko) | 2022-11-21 |
| JPWO2021182377A1 (zh) | 2021-09-16 |
| EP4119150A1 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6944399B2 (ja) | プロバイオティクス細菌 | |
| US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
| Bowler et al. | Wound microbiology and associated approaches to wound management | |
| CN102639129B (zh) | 含游离脂肪酸的抗微生物组合物 | |
| CN108135947A (zh) | 提高免疫应答和皮肤和/或粘膜屏障功能的材料和方法 | |
| CN103409334B (zh) | 抑制***炎病原菌之乳酸杆菌及其用途 | |
| KR20070062945A (ko) | 고분자량의 ｐｅｇ-유사 화합물을 포함하는 치료학적수송 시스템 | |
| BR112019011015A2 (pt) | uso de uma composição, formulação e seu uso, lubrificante vaginal prebiótico e uso de uma cápsula vaginal simbiótica | |
| CN107735083A (zh) | 抗菌组合物 | |
| CN113278548A (zh) | 卷曲乳杆菌及在生产改善人体***环境的产品中的应用 | |
| Vale et al. | Corynebacterium bovis as a cause of human disease | |
| WO1986007258A1 (en) | Anti-bacterial methods and agent | |
| JPH02503800A (ja) | 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤 | |
| CN115135332A (zh) | 艰难梭菌增殖抑制剂 | |
| CN114657106A (zh) | 一株植物乳植杆菌及其在防治痤疮中的应用 | |
| CN112402463B (zh) | 一种用于抑制***炎症的复合益生菌及其制品和应用 | |
| CN110381933A (zh) | 用于控制生物膜的材料和方法 | |
| CN113308405A (zh) | 一种新型的双益生菌协同复合菌剂及其应用 | |
| McKinney | Lippincott's Guide to Infectious Diseases | |
| CN114891692B (zh) | 一种改善人体***环境的菌株及其应用 | |
| Brook | Anaerobic infections | |
| Kudavidanage et al. | Comparison of Three Skin Disinfectant Solutions used for Skin Preparation prior to Spinal and Epidural Anaesthetic Procedures in Parturients at De Soyza Maternity Hospital and Castle Street Hospital for Women | |
| JP2018002661A (ja) | 抗菌防腐剤組成物及びそれを用いた組成物 | |
| Browning et al. | The chemotherapy of pyogenic infections with special reference to the antiseptic properties of acridine compounds | |
| CN114099640A (zh) | 用于抑杀幽门螺杆菌的抗菌肽组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |